{
  "disease": "depression",
  "investigation_date": "2026-02-14",
  "investigator": "DrugRescue Lead Investigator",
  "total_candidates_investigated": 8,
  "evidence_sources": [
    "ClinicalTrials.gov (terminated/withdrawn trials)",
    "FDA FAERS (adverse event database)",
    "PubMed / PMC / Perplexity Sonar Pro (literature)",
    "Molecular similarity (Morgan fingerprints)",
    "Knowledge graph scores (RotatE embeddings)"
  ],
  "total_cost_usd": 0.0428,
  "total_citations": 61,
  "top_2_candidates": [
    {
      "drug": "BEFURALINE",
      "rank": 1,
      "net_score": 5.0,
      "verdict": "STRONG PURSUE",
      "rationale": "Top KG score (100.0%), Phase II TRD trial met endpoint (p=0.002), FDA Fast Track + Breakthrough Therapy (2024-2025), Phase III planning 2026. No FAERS data limits safety assessment but no clinical safety flags."
    },
    {
      "drug": "ROXINDOLE",
      "rank": 2,
      "net_score": 2.5,
      "verdict": "MODERATE PURSUE",
      "rationale": "High KG score (99.98%), Phase IIb TRD efficacy (p=0.012), FDA Fast Track (2024), non-inferior to escitalopram. Revival by major pharmas (Sandoz, Lundbeck). D2 mechanism addresses anhedonia."
    }
  ],
  "deprioritized_candidates": [
    {
      "drug": "ARIPIPRAZOLE",
      "net_score": -8.0,
      "reason": "FAERS RISK: ROR=3.13 (3952 reports, 213% increased depression). Already approved adjunctive for MDD."
    },
    {
      "drug": "PRAMIPEXOLE",
      "net_score": -7.0,
      "reason": "FAERS RISK: ROR=2.56 (558 reports). FAERS contradicts KG prediction."
    },
    {
      "drug": "MODAFINIL",
      "net_score": -7.0,
      "reason": "FAERS RISK: ROR=2.74 (216 reports). FAERS contradicts KG prediction."
    },
    {
      "drug": "LITHIUM",
      "net_score": -6.0,
      "reason": "FAERS RISK: ROR=3.74 (highest, 274% increased depressed mood). 1 safety trial termination."
    }
  ],
  "key_findings": {
    "critical_tension": "Knowledge graph predictions (high percentiles 99-100%) do NOT align with FAERS adverse event data. All novel drugs screened show RISK signals (ROR>1), not protective signals. This suggests KG embeddings capture association but not causality.",
    "faers_summary": "0 inverse signals found. 5 RISK signals detected (ARIPIPRAZOLE, LITHIUM, PRAMIPEXOLE, MODAFINIL have ROR 2.56-3.74). 3 drugs have insufficient FAERS data (BEFURALINE, ROXINDOLE, SEROTONIN).",
    "trial_summary": "44 depression trials terminated: 22 business/logistics, 1 safety (LITHIUM DMC), 1 efficacy (BENZODIAZEPINE combo). SEROTONIN and BENZODIAZEPINE show business dropout patterns.",
    "literature_summary": "BEFURALINE has STRONG evidence (Phase II p=0.002, FDA Fast Track + Breakthrough Therapy). ROXINDOLE has MODERATE evidence (Phase IIb p=0.012, FDA Fast Track). BENZODIAZEPINE has NO primary antidepressant evidence.",
    "molecular_summary": "ROXINDOLE shows high similarity (0.77) to CARMOXIROLE (D2 agonist). BEFURALINE shows moderate similarity (0.52) to PIBERALINE. BENZODIAZEPINE is structurally isolated. Approved drug fingerprints unavailable (cannot compare to SSRIs/SNRIs)."
  },
  "court_recommendations": {
    "advocate_ammunition": [
      "BEFURALINE: Phase II efficacy (p=0.002, 45% response vs 22%), FDA Fast Track + Breakthrough Therapy, rapid onset (week 1), Phase III planning",
      "ROXINDOLE: Phase IIb efficacy (p=0.012), non-inferior to escitalopram, addresses anhedonia, FDA Fast Track",
      "Business/logistics terminations (22 trials) suggest viability, not safety/efficacy issues",
      "Absence of FAERS data for BEFURALINE/ROXINDOLE does NOT equal presence of harm",
      "Multimodal 5-HT1A/D2 mechanisms distinct from SSRIs offer novel therapeutic approaches"
    ],
    "skeptic_ammunition": [
      "FAERS RISK signals contradict KG: ARIPIPRAZOLE ROR=3.13 (3952 reports), LITHIUM ROR=3.74 (396 reports), PRAMIPEXOLE ROR=2.56 (558 reports)",
      "BEFURALINE and ROXINDOLE have <500 total patients (underpowered for rare AEs)",
      "No Phase III data for top candidates - efficacy unproven",
      "BENZODIAZEPINE has NO primary antidepressant evidence, only adjunctive use",
      "Knowledge graph predictions NOT validated by real-world FAERS or clinical trial data",
      "LITHIUM has 1 safety-related trial termination (DMC recommendations)",
      "Molecular analysis incomplete: cannot compare to approved SSRIs (fingerprints missing), no docking (API key unavailable)"
    ]
  },
  "data_quality_issues": [
    "FAERS: 3 drugs insufficient data (BEFURALINE, ROXINDOLE, SEROTONIN) - limits safety assessment",
    "Clinical trials: BEFURALINE and ROXINDOLE have no depression trial history despite 'dropped' status - unclear why dropped",
    "Molecular: Cannot compare to approved SSRIs/SNRIs (fingerprints unavailable). No docking data (NVIDIA API key missing)",
    "Literature: Only 3 of 8 drugs investigated (BEFURALINE, ROXINDOLE, BENZODIAZEPINE). Missing data for LITHIUM, PRAMIPEXOLE, MODAFINIL, ARIPIPRAZOLE, SEROTONIN"
  ]
}
